Cambridge Healthtech Institute’s 3rd Annual
Artificial Intelligence in Clinical Research
Machine Learning and AI to Advance Clinical Operations and Data Management
February 20-21, 2020
Artificial intelligence (AI) and machine learning (ML) have propelled many industries toward a new, highly functional and powerful state. Now they are starting to make their way into the clinical research realm advancing clinical operations, as well as
data management. Many pharmaceutical companies and larger CROs are starting projects involving some elements of AI, ML, and robotic process automation in clinical trials. CHI’s 3rd Annual Artificial Intelligence in Clinical Research conference
is designed to facilitate the discussion and to accelerate the adoption of these approaches in clinical trials.
Arrive early and attend Part 1 (Wed - Thurs): Clinical Data Strategy and Analytics
Final Agenda
Thursday, February 20
11:30 am Registration Open (Regency Rotunda)
12:30 pm BRIDGING LUNCHEON CO-PRESENTATION: Precision Medicine: Why Real-Time Insights Are More Important than Ever
Anand Dubey, Associate Director, Business Solution Architect, Saama Technologies
Len Rosenberg, PhD, RPh Head, Clinical Operations, The Leukemia & Lymphoma Society/Beat AML LLC
Complex Master Trials with numerous sub-protocols present distinct challenges for sponsors. Because treatments are tailored to individuals based on factors like genetic makeup, data must be managed effectively. Using the LLS’s groundbreaking Beat
AML Master Clinical Trial as an example, this presentation will explain how studies applying precision medicine benefit from technologies, including AI, that deliver insights based on quality data and real-time analytics.
1:00 Coffee and Dessert Break in the Exhibit Hall (Windermere Ballroom)
2:00 Afternoon Plenary Keynotes (Regency Ballroom S)
3:10 Booth Crawl & Refreshment Break in the Exhibit Hall. Last Chance for Exhibit Viewing (Windermere Ballroom)
4:10 NEW: Chairperson’s Remarks
Wael Salloum, PhD, CSO & Co-Founder, Mendel.ai
4:15 NEW: AI in Drug Development and Clinical Trials
Shameer Khader, PhD, Senior Director, Advanced Analytics, Data Science & Bioinformatics, AstraZeneca
This talk will focus on the myriad of AI applications in the drug development process, with a focus on designing and executing clinical trials. The discussion will be motivated by examples and will cover issues, such as data processing and preparation,
design of robust AI solutions, challenges in scaling and productionalizing pilot prototypes, and much more.
4:45 NEW: Explainability in AI and How it is Transforming R&D
Lucas Glass, Global Head, IQVIA Analytics Center of Excellence, IQVIA
The data output of Clinical research has created vast opportunities to transform our industry. Many have identified artificial intelligence (AI) and machine learning (ML) as fundamental to that transformation. IQVIA will share examples
of AI/ML and analytics in use today, cite benefits being generated, and how ‘Explainability’ helps us realize those benefits. Use cases and lessons learned include: › Study design › Site ID & patient population identification
› Safety automation › Clinical monitoring/risk-based monitoring
5:15 NEW: Clinical Pitfalls in Using AI for Decision Support
Sujay
Kakarmath, MD, MS, Lead Scientist, Data Science and Artificial Intelligence, Partners Healthcare Pivot Labs
Traditional metrics used to evaluate the performance of AI solutions suffice to establish a proof-of-concept. For real-world applications, however, these metrics are far from sufficient in establishing clinical utility. The Data Science and AI team
at Partners Healthcare Pivot Labs invests a great deal of time thinking about the right questions, working out potential pitfalls and developing best practices in evaluating AI solutions for healthcare. This presentation will share insights obtained
from real projects.
Barrel Spring
5:45 NEW: PANEL DISCUSSION: Scaling Innovation
Moderator: Craig
Lipset, Independent Advisor, Former Head of Clinical Innovation, Pfizer
Panelists: Tammy Guld, Global Lead, Janssen Clinical Innovation
Emmanuel Fombu, MD, MBA, Vice President, Locust Walk
Jacob LaPorte, PhD, Patient; Co-Founder & Vice President, Global Head of BIOME – The Digital Innovation Lab, Novartis
Alex Simmonds, Head, Clinical Trial Solutions, Varian Medical Systems
Digital tools can generate a great deal of buzz and attention, but most companies today are exploring and experimenting with similar digital solutions. What will set companies apart is not whether they can find digital tools or pilot solutions, but
which companies are able to implement and scale digital solutions across their development organization.
- Explore how companies are organizing themselves to scout, pilot and scale digital solutions
- Identify strengths across various models -- from centralized digital and innovation teams to capabilities being embedded with business owners
- Share best practices to move innovation “beyond the pilot”
6:15 Networking Reception (Manatee and Spring Foyer)
7:15 Close of Day
Friday, February 21
7:15 am Registration Open (Regency Rotunda)
7:45 BREAKFAST PRESENTATION: Breaking
Down the Roadblocks to Site Activation (Regency Ballroom T)
Jill
Johnston President, Study Planning & Site Optimization, WCG
8:15 Session Break
8:20 Chairperson’s Remarks
Malaikannan
Sankarasubbu, Vice President, AI Research, Saama Technologies
8:25 CO-PRESENTATION: Intelligent Machines Take on Clinical Data Management
Prasanna Rao, Head, AI & Data Science, Data Monitoring and Management, Clinical Sciences and Operations, Global Product Development, Pfizer
Ashley Howard, Associate Director, Asset Lead – Oncology, Pfizer
In this session, we will discuss how Artificial Intelligence will transform Clinical Data Management. The human versus machine battle has already started in other industries. How can we leverage machines to not just perform repetitive data cleaning
tasks, but take on higher complexity tasks in tandem with humans?
8:55 NEW: Accelerating Clinical Database Set-Up Using Machine Learning & AI
Abhishek Kadam, Associate Director, Data Operations, Clinical Data Management, Novartis
Have you ever wondered how to get the best experience for end users while defining data collection and reporting requirements during the study start-up phase? Does this process take too long in your company? How can technology be used to drive down
timelines, improve quality, increase standardization and downstream impact? This presentation will give insights into the work being done at Novartis to achieve all these using historical data.
9:15 AI/ML – Will it Revolutionize Clinical Data Management?
Francis
Kendall, Senior Director, Biostatistics & Programming, Cytel
This talk will look at AI/ML within the context of how it could revolutionize Clinical Data Management. It will outline the assumptions of how the scope of Clinical Data Management will widen and what factors will need to be in place to allow for
the effective application of AI/ML. Finally, it will provide a few case studies on how AI/ML is being applied in Clinical Data Management.
9:35 The Application of Intelligent Automation Technologies in Pharmacovigilance
Robert Taylor, Director, Safety Management, Global Regulatory Affairs and Clinical Safety, Merck
The application of intelligent automation technologies to PV processes has the potential to improve quality, consistency, and efficiency with the ultimate goal of improving patient safety. Automating areas where available data continues to increase
can facilitate that goal by optimizing human resources within the areas of higher value to patient safety. To accomplish this, PV organizations must continually oversee the applicability, design, deployment, performance, validation, and updating
of these technologies. Our proposed validation framework seeks to build on early seminal works while incorporating best practices from other industries and TransCelerate member companies.
9:55 Accessing Meaningful Subject Data and Clinical Insights Throughout the Clinical Trial Process
Michelle Marlborough, Chief Product Officer, Product Management, AiCure
Data are generated at nearly every stage of the clinical trial life cycle, from collection of baseline subject data at enrollment to the analysis of the data set. Accessing meaningful subject data and obtaining insights into real-time engagement
make a major difference between probability of staying in treatment and discontinuation.
10:25 Networking Coffee Break (Session Room Foyer)
10:55 Chairperson’s Remarks
Francis Kendall, Senior Director, Biostatistics & Programming, Cytel
11:00 CASE STUDY: Can Artificial Intelligence Identify Recurring Quality Issues?
Faye O’Brien, Director, Performance & Metrics, AstraZeneca
Mining, Categorizing and Analyzing quality data through machine learning has the potential to improve clinical trial delivery processes.
11:30 In-Silico Patients
Wael Salloum, PhD, CSO & Co-Founder, Mendel.ai
AI technologies can generate digital patients as a substitute for human subjects. Although this may sound like science fiction today, it definitely won’t in a few years. We have already achieved the first few milestones: synthesizing a digital
copy of a patient journey from EHR records and building technologies to interrogate these digital replicas to generate clinical evidence. The future is patientless.
12:00 pm Transition to Shared Sessions
12:00 Chairperson’s Remarks
Prasanna Rao, Head, AI & Data Science, Data Monitoring and Management, Clinical Sciences and Operations, Global Product Development, Pfizer Inc.
12:05 Re-Skilling for AI/ML: Leveraging Your SMEs
Nechama Katan, Associate Director, Data Monitoring and Management, Clinical Sciences and Operations, Global Product Development, Pfizer
AI/ML are very powerful tools for clinical trials. However, there is a gap between those that understand what AI/ML can do for the business and the business SME (subject matter experts) who really understand the business problems. Without strong
SME engagement in solutions, technical solutions are often at risk. This talk will review successful case studies for developing “lego” employees/teams who help bridge the gaps between AI/ML technologist and the SMEs. We will discuss
both the how and what that makes an AI/ML project successful in clinical trials.
12:25 PANEL DISCUSSION: AI Implementation: Technology, Data, People
Moderator: Prasanna Rao, Head, AI & Data Science, Data Monitoring and Management, Clinical Sciences and Operations, Global Product Development, Pfizer
Panelists: Balazs Flink, PhD, Head, Clinical Trial Analytics, R&D Business Insights, Bristol-Myers Squibb
Abhishek Kadam, Associate Director, Data Operations, Clinical Data Management, Novartis
Malaikannan Sankarasubbu, Vice President, AI Research, Saama Technologies
Shameer Khader, PhD, Senior Director, Advanced Analytics, Data Science & Bioinformatics, AstraZeneca
It was proven that machine learning and AI can aid clinical development in various aspects. With evolving AI technology implementation challenges become more and more noticeable. This panel discussion will brainstorm the key pain points of AI
implementation:
- What is the best technology and how to work with technology providers?
- How to make all data machine learnable and available for AI applications
- How to solve “the people puzzle”
1:05 Transition to Lunch
1:10 SCOPE Send Off Luncheon Presentation: Proven,
Pragmatic Applications of Artificial Intelligence in Safety Reporting
Steven
Beales Senior Vice President, Safety Solutions Scientific & Regulatory
Review WCG
1:40 Closing Remarks
1:45 SCOPE Summit 2020 Adjourns